Symposium 1: Overnutrition: Consequences and solutions Non-alcoholic fatty liver disease: The hepatic consequence of obesity and the metabolic syndrome

Proceedings of the Nutrition Society

Volumn 69, Issue 2, 2010, Pages 211-220

  Moore, J Bernadette ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Metabolic syndrome; Non alcoholic fatty liver disease; Systems biology

Indexed keywords

CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE COURSE; DYSLIPIDEMIA; FATTY LIVER; GENETIC POLYMORPHISM; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVERNUTRITION; SYSTEMS BIOLOGY; TREATMENT RESPONSE; REVIEW;

DISEASE PROGRESSION; FATTY LIVER; HUMANS; METABOLIC SYNDROME X; OBESITY; SYSTEMS BIOLOGY;

EID: 77955507529     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665110000030     Document Type: Conference Paper

References (124)

1. Adler M & Schaffner F (1979) Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 67, 811-816. (Pubitemid 10218835)
2. Ludwig J, Viggiano TR, McGill DB et al. (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55, 434-438. (Pubitemid 10057164)
3. Day CP & James OF (1998) Steatohepatitis: a tale of two 'hits'? Gastroenterology 114, 842-845.
4. Vuppalanchi R & Chalasani N (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49, 306-317.
5. Mofrad P, Contos MJ, Haque M et al. (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37, 1286-1292. (Pubitemid 36667307)
6. Schwenzer NF, Springer F, Schraml C et al. (2009) Noninvasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51, 433-445.
7. Browning JD, Szczepaniak LS, Dobbins R et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387-1395. (Pubitemid 39657013)
8. Yoneda M, Yoneda M, Mawatari H et al. (2008) Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 40, 371-378.
9. Huwart L, Sempoux C, Vicaut e et al. (2008) Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135, 32-40. (Pubitemid 351899024)
10. Foucher J, Castera L, Bernard PH et al. (2006) Prevalence and factors associated with failure of liver stiffness measurement using Fibro Scan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 18, 411-412.
11. Salameh N, Larrat B, Abarca-Quinones J et al. (2009) Early detection of steatohepatitis in fatty rat liver by using MR elastography. Radiology 253, 90-97.
12. Poynard T, Ratziu V, Naveau S et al. (2005) The diagnostic value of biomarkers (Steato Test) for the prediction of liver steatosis. Comp Hepatol 4, 10. (Pubitemid 43046111)
13. Poynard T, Ratziu V, Charlotte F et al. (2006) Diagnostic value of biochemical markers (Nash Test) for the prediction of non alcoholo steato hepatitis in patients with nonalcoholic fatty liver disease. BMC Gastroenterol 6, 34. (Pubitemid 43308995)
14. Guha IN, Parkes J, Roderick P et al. (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47, 455-460. (Pubitemid 351280713)
15. Cadranel JF, Rufat P & Degos F (2000) Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 32, 477-481.
16. Gilmore IT, Burroughs A, Murray-Lyon IM et al. (1995) Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 36, 437-441.
17. Ratziu V, Charlotte F, Heurtier A et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128, 1898-1906. (Pubitemid 40824701)
18. Wieckowska A, McCullough AJ & Feldstein AE (2007) Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46, 582-589. (Pubitemid 47344794)
19. Hilden M, Christoffersen P, Juhl E et al. (1977) Liver histology in a 'normal' population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12, 593-597. (Pubitemid 8149779)
20. Wanless IR & Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12, 1106-1110.
21. Bellentani S, Saccoccio G, Masutti F et al. (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132, 112-117. (Pubitemid 30044177)
22. Dassanayake AS, Kasturiratne A, Rajindrajith S et al. (2009) Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 24, 1284-1288.
23. Garcia-Monzon C, Martin-Perez E, Iacono OL et al. (2000) Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33, 716-724.
24. Ratziu V, Giral P, Charlotte F et al. (2000) Liver fibrosis in overweight patients. Gastroenterology 118, 1117-1123. (Pubitemid 30346988)
25. Dixon JB, Bhathal PS & O'Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121, 91-100. (Pubitemid 32591518)
26. Del Gaudio A, Boschi L, Del Gaudio GA et al. (2002) Liver damage in obese patients. Obes Surg 12, 802-804. (Pubitemid 36135524)
27. Gholam PM, Flancbaum L, Machan JT et al. (2007) Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 102, 399-408. (Pubitemid 46160554)
28. Gupte P, Amarapurkar D, Agal S et al. (2004) Nonalcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 19, 854-858. (Pubitemid 39093200)
29. Targher G, Bertolini L, Padovani R et al. (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30, 1212-1218. (Pubitemid 46684650)
30. Leite NC, Salles GF, Araujo AL et al. (2009) Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29, 113-119.
31. Weston SR, Leyden W, Murphy R et al. (2005) Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41, 372-379. (Pubitemid 40165382)
32. Schwimmer JB, Deutsch R, Kahen T et al. (2006) Prevalence of fatty liver in children and adolescents. Pediatrics 118, 1388-1393. (Pubitemid 46393782)
33. Chan DF, Li AM, Chu WC et al. (2004) Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 28, 1257-1263.
34. Sagi R, Reif S, Neuman G et al. (2007) Nonalcoholic fatty liver disease in overweight children and adolescents. Acta Paediatr 96, 1209-1213. (Pubitemid 47106536)
35. Sartorio A, Del Col A, Agosti F et al. (2007) Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 61, 877-883. (Pubitemid 47040311)
36. Damaso AR, do Prado WL, de Piano A et al. (2008) Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Dig Liver Dis 40, 132-139.
37. Lobstein T & Jackson-Leach R (2006) Estimated burden of paediatric obesity and co-morbidities in Europe. Part 2. Numbers of children with indicators of obesity-related disease. Int J Pediatr Obes 1, 33-41.
38. Schwimmer JB, Pardee PE, Lavine JE et al. (2008) Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 118, 277-283.
39. Pacifico L, Cantisani V, Ricci P et al. (2008) Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res 63, 423-427. (Pubitemid 351450591)
40. Jackson-Leach R & Lobstein T (2006) Estimated burden of paediatric obesity and co-morbidities in Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing. Int J Pediatr Obes 1, 26-32.
41. Charlton M (2007) Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. Am J Gastroenterol 102, 409-411. (Pubitemid 46160555)
42. Musso G, Gambino R & Cassader M (2009) Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48, 1-26.
43. Parekh S & Anania FA (2007) Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132, 2191-2207. (Pubitemid 46693752)
44. Donnelly KL, Smith CI, Schwarzenberg SJ et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 1343-1351.
45. Fabbrini E, Mohammed BS, Magkos F et al. (2008) Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134, 424-431. (Pubitemid 351173050)
46. Guerrero R, Vega GL, Grundy SM et al. (2009) Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 49, 791-801.
47. Bacon BR, Farahvash MJ, Janney CG et al. (1994) Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107, 1103-1109.
48. Browning JD & Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114, 147-152. (Pubitemid 39071617)
49. Anderson N & Borlak J (2008) Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60, 311-357.
50. Tsochatzis EA, Papatheodoridis GV & Archimandritis AJ (2009) Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009, 831670.
51. Dam-Larsen S, Franzmann M, Andersen IB et al. (2004) Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53, 750-755. (Pubitemid 38561456)
52. Matteoni CA, Younossi ZM, Gramlich T et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413-1419. (Pubitemid 29258890)
53. Fassio E, Alvarez E, Dominguez N et al. (2004) Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40, 820-826. (Pubitemid 39288114)
54. Ekstedt M, Franzen LE, Mathiesen UL et al. (2006) Longterm follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873. (Pubitemid 46489550)
55. Ratziu V, Bugianesi E, Dixon J et al. (2007) Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther 26, 821-830. (Pubitemid 47346702)
56. Sanyal AJ, Banas C, Sargeant C et al. (2006) Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43, 682-689.
57. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S et al. (2009) The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58, 1538-1544.
58. Angulo P, Keach JC, Batts KP et al. (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30, 1356-1362.
59. Adams LA, Sanderson S, Lindor KD et al. (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42, 132-138. (Pubitemid 40038911)
60. Rafiq N, Bai C, Fang Y et al. (2009) Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7, 234-238.
61. Marchesini G, Bugianesi E, Forlani G et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917-923. (Pubitemid 36397405)
62. Gramlich T, Kleiner DE, McCullough AJ et al. (2004) Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 35, 196-199. (Pubitemid 38240902)
63. Argo CK, Northup PG, Al-Osaimi AM et al. (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51, 371-379.
64. Crowther MA & Cook DJ (2007) Trials and tribulations of systematic reviews and meta-analyses. Hematology Am Soc Hematol Educ Program 2007, 493-497.
65. Adams LA, Lymp JF, St Sauver J et al. (2005) The natural history of nonalcoholic fatty liver disease: a populationbased cohort study. Gastroenterology 129, 113-121. (Pubitemid 41002048)
66. Ong JP, Pitts A & Younossi ZM (2008) Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49, 608-612.
67. Dunn W, Xu R, Wingard DL et al. (2008) Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 103, 2263-2271.
68. Ruhl CE & Everhart JE (2009) Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 136, 477-485. e411.
69. Struben VM, Hespenheide EE & Caldwell SH (2000) Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 108, 9-13.
70. Willner IR, Waters B, Patil SR et al. (2001) Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 96, 2957-2961. (Pubitemid 32959539)
71. Musso G, Gambino R, De Michieli F et al. (2008) Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology 47, 1167-1177. (Pubitemid 351547903)
72. Tokushige K, Hashimoto E, Noto H et al. (2009) Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. J Gastroenterol 44, 976-982.
73. Carulli L, Canedi I, Rondinella S et al. (2009) Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with nonalcoholic steatohepatitis. Dig Liver Dis 41, 823-828.
74. Tokushige K, Takakura M, Tsuchiya-Matsushita N et al. (2007) Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 46, 1104-1110. (Pubitemid 46669735)
75. Sazci A, Akpinar G, Aygun C et al. (2008) Association of apolipoprotein e polymorphisms in patients with nonalcoholic steatohepatitis. Dig Dis Sci 53, 3218-3224. (Pubitemid 351613167)
76. Romeo S, Kozlitina J, Xing C et al. (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40, 1461-1465.
77. Yuan X, Waterworth D, Perry JR et al. (2008) Populationbased genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 83, 520-528.
78. Musso G, Gambino R, De Michieli F et al. (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37, 909-916. (Pubitemid 36397404)
79. Toshimitsu K, Matsuura B, Ohkubo I et al. (2007) Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 23, 46-52. (Pubitemid 44959764)
80. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al. (2007) Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD) : a population based study. J Hepatol 47, 711-717. (Pubitemid 47503432)
81. Kim CH, Kallman JB, Bai C et al. (2010) Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg 20, 154-160.
82. Spadaro L, Magliocco O, Spampinato D et al. (2008) Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 40, 194-199. (Pubitemid 351181793)
83. Zhu FS, Liu S, Chen XM et al. (2008) Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 14, 6395-6400.
84. Solga S, Alkhuraishe AR, Clark JM et al. (2004) Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 49, 1578-1583. (Pubitemid 39335538)
85. Kang H, Greenson JK, Omo JT et al. (2006) Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 101, 2247-2253. (Pubitemid 44477551)
86. Bruce KD, Cagampang FR, Argenton M et al. (2009) Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology 50, 1796-1808.
87. McCurdy CE, Bishop JM, Williams SM et al. (2009) Maternal high-fat diet triggers lipotoxicity in the Fetal livers of nonhuman primates. J Clin Invest 119, 323-335.
88. Lirussi F, Azzalini L, Orando S et al. (2007) Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews 2007, issue 1, CD004996. Chichester, West Sussex: John Wiley and Sons, Ltd. (Pubitemid 351820394)
89. Lavine JE (2000) Vitamin e treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136, 734-738. (Pubitemid 30415645)
90. Kugelmas M, Hill DB, Vivian B et al. (2003) Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38, 413-419. (Pubitemid 36919862)
91. Harrison SA, Torgerson S, Hayashi P et al. (2003) Vitamin e and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98, 2485-2490. (Pubitemid 37448761)
92. Chalasani NP, Sanyal AJ, Kowdley KV et al. (2009) Pioglitazone versus vitamin e versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 30, 88-96.
93. Lavine JE, Schwimmer JB, Molleston JP et al. (2010) Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 31, 62-70.
94. Brun P, Castagliuolo I, Di Leo V et al. (2007) Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 292, G518-G525. (Pubitemid 46263521)
95. Wigg AJ, Roberts-Thomson IC, Dymock RB et al. (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48, 206-211.
96. Sabate JM, Jouet P, Harnois F et al. (2008) High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 18, 371-377.
97. Sajjad A, Mottershead M, Syn WK et al. (2005) Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 22, 291-299. (Pubitemid 41207458)
98. Loguercio C, Federico A, Tuccillo C et al. (2005) Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 39, 540-543. (Pubitemid 40863651)
99. Li Z, Yang S, Lin H et al. (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37, 343-350. (Pubitemid 36152533)
100. Velayudham A, Dolganiuc A, Ellis M et al. (2009) VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49, 989-997.
101. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607.
102. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497.
103. Clark JM, Brancati FL & Diehl AM (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98, 960-967. (Pubitemid 36733754)
104. Fan JG, Zhu J, Li XJ et al. (2005) Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 20, 1825-1832. (Pubitemid 43961036)
105. Kim HC, Choi SH, Shin HW et al. (2005) Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World J Gastroenterol 11, 5314-5321.
106. Hamaguchi M, Kojima T, Takeda N et al. (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143, 722-728. (Pubitemid 41692529)
107. Brea A, Mosquera D, Martin E et al. (2005) Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25, 1045-1050. (Pubitemid 40627853)
108. Targher G, Bertolini L, Padovani R et al. (2006) Nonalcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest 29, 55-60. (Pubitemid 43355836)
109. Aygun C, Kocaman O, Sahin T et al. (2008) Evaluation of metabolic syndrome frequency and carotid artery intimamedia thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 53, 1352-1357. (Pubitemid 351514649)
110. Fracanzani AL, Valenti L, Bugianesi E et al. (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48, 792-798.
111. Kim HC, Kim DJ & Huh KB (2009) Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 204, 521-525.
112. McKimmie RL, Daniel KR, Carr JJ et al. (2008) Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 103, 3029-3035.
113. Sookoian S & Pirola CJ (2008) Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 49, 600-607.
114. Targher G, Bertolini L, Rodella S et al. (2007) Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30, 2119-2121. (Pubitemid 47219432)
115. Hamaguchi M, Kojima T, Takeda N et al. (2007) Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13, 1579-1584. (Pubitemid 46672668)
116. Choi SY, Kim D, Kim HJ et al. (2009) The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 104, 1953-1960.
117. Schindhelm RK, Dekker JM, Nijpels G et al. (2007) Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191, 391-396. (Pubitemid 46400701)
118. Wilson PW, D'Agostino RB, Levy D et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847. (Pubitemid 28213628)
119. Hood L, Heath JR, Phelps ME et al. (2004) Systems biology and new technologies enable predictive and preventative medicine. Science 306, 640-643. (Pubitemid 39440903)
120. Weston AD & Hood L (2004) Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 3, 179-196. (Pubitemid 38500984)
121. Calvert VS, Collantes R, Elariny H et al. (2007) A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 46, 166-172. (Pubitemid 47171933)
122. Charlton M, Viker K, Krishnan A et al. (2009) Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology 49, 1375-1384.
123. Bell LN, Theodorakis JL, Vuppalanchi R et al. (2010) Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 51, 111-120.
124. British Liver Trust (2009) Facts about liver disease. http://www.britishlivertrust.org.uk/home/media-centre/facts-aboutliver-disease. aspx (accessed June 2009).